English  Chinese  Germany

(AR)-A-CYCLOPENTYL-A-HYDROXY-N-[1-(4-METHYL-3-PENTENYL)-4-PIPERIDINYL]BENZENEACETAMIDE FUMARATE

CAS番号.244277-89-2
化学名:
别名:
英語化学名:(AR)-A-CYCLOPENTYL-A-HYDROXY-N-[1-(4-METHYL-3-PENTENYL)-4-PIPERIDINYL]BENZENEACETAMIDE FUMARATE
英語别名:J 104129 FUMARATE;(αR)-α-Cyclopentyl-α-hydroxy-N-[1-(4-methyl-3-pentenyl)-4-piperidinyl]benzeneacetamidefumarate;(AR)-A-CYCLOPENTYL-A-HYDROXY-N-[1-(4-METHYL-3-PENTENYL)-4-PIPERIDINYL]BENZENEACETAMIDE FUMARATE
CBNumber:CB12450341
分子式:C24H36N2O2.C4H4O4
分子量:500.632
MOL File:244277-89-2.mol
(AR)-A-CYCLOPENTYL-A-HYDROXY-N-[1-(4-METHYL-3-PENTENYL)-4-PIPERIDINYL]BENZENEACETAMIDE FUMARATE 物理性質
貯蔵温度 : Store at +4°C
安全性情報

(AR)-A-CYCLOPENTYL-A-HYDROXY-N-[1-(4-METHYL-3-PENTENYL)-4-PIPERIDINYL]BENZENEACETAMIDE FUMARATE 化学特性,用途語,生産方法

生物活性
Potent M 3 muscarinic receptor antagonist that displays ~ 120-fold selectivity over M 2 receptors (K i values are 4.2, 19 and 490 nM for human M 3 , M 1 and M 2 receptors respectively). Exhibits > 250-fold bronchial selectivity; inhibits ACh-induced bronchoconstriction but not ACh-induced bradycardia (K B values are 3.3 and 170 nM for rat trachea M 3 and rat right atria M 2 receptors respectively).
(AR)-A-CYCLOPENTYL-A-HYDROXY-N-[1-(4-METHYL-3-PENTENYL)-4-PIPERIDINYL]BENZENEACETAMIDE FUMARATE 上流と下流の製品情報
原材料
準備製品
(AR)-A-CYCLOPENTYL-A-HYDROXY-N-[1-(4-METHYL-3-PENTENYL)-4-PIPERIDINYL]BENZENEACETAMIDE FUMARATE 生産企業      Global( 3)Suppliers     
名前電話番号ファックス番号電子メール国籍製品カタログ優位度
3B Pharmachem (Wuhan) International Co.,Ltd. 86-21-50328103 * 801、802、803、804 Mobile:1893055203786-21-5032810967055399@qq.comCHINA 15983 69
EMMX Biotechnology LLC 888-539-0666888-539-0666info@emmx.comUSA 8489 60
 
244277-89-2((AR)-A-CYCLOPENTYL-A-HYDROXY-N-[1-(4-METHYL-3-PENTENYL)-4-PIPERIDINYL]BENZENEACETAMIDE FUMARATE) キーワード:
244277-89-2 (AR)-A-CYCLOPENTYL-A-HYDROXY-N-[1-(4-METHYL-3-PENTENYL)-4-PIPERIDINYL]BENZENEACETAMIDE FUMARATE J 104129 FUMARATE (αR)-α-Cyclopentyl-α-hydroxy-N-[1-(4-methyl-3-pentenyl)-4-piperidinyl]benzeneacetamidefumarate
Copyright 2007 © ChemicalBook. All rights reserved